SCHEDULE 13G: Rubric Capital Management and David Rosen Disclose 7.29% Stake in Collegium Pharmaceutical
Beneficial Ownership Report
Rubric Capital Management LP and David Rosen have jointly disclosed a beneficial ownership of 7.29% in Collegium Pharmaceutical, Inc., totaling 2,350,000 shares of common stock as of December 31, 2024.
Summary
- Rubric Capital Management LP and David Rosen have jointly filed a Schedule 13G, reporting beneficial ownership of Collegium Pharmaceutical, Inc.
- As of December 31, 2024, the reporting persons collectively beneficially own 2,350,000 shares of Collegium Pharmaceutical's common stock.
- This ownership represents 7.29% of the outstanding common stock of Collegium Pharmaceutical, Inc.
- The percentage is calculated based on 32,250,236 shares outstanding as of October 31, 2024, as reported in the Issuer's Form 10-Q.
- Rubric Capital Management LP acts as an investment adviser to certain investment funds and accounts (Rubric Funds) that hold these shares.
- David Rosen is the Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital.
- The shares are held with shared voting and shared dispositive power by the reporting persons.
- The acquisition of these securities was made in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The filing indicates a substantial investment by Rubric Capital Management LP and David Rosen in Collegium Pharmaceutical, Inc., which can be interpreted as a positive signal of investor confidence in the company's prospects. However, the document itself is a factual disclosure of ownership and does not contain performance metrics or forward-looking statements from the issuer.
Positives
- Rubric Capital Management LP and David Rosen have acquired a significant 7.29% stake in Collegium Pharmaceutical, Inc., indicating a notable investment position.
- The acquisition was stated to be in the ordinary course of business, suggesting a long-term investment perspective rather than an activist intent to change control.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.
- The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
- By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
This filing indicates a significant investment by an institutional asset manager in a pharmaceutical company. While the filing itself does not provide industry-specific analysis, it highlights continued investor interest in the pharmaceutical sector, particularly in companies like Collegium Pharmaceutical, Inc.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake (7.29%) by Rubric Capital Management LP and David Rosen may influence market perception and potentially the stock price, as it signals confidence from a notable investor.
- Management: Awareness of a significant institutional shareholder may influence management's strategic decisions, though the filing states the stake is not for control purposes.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (ownership threshold met). |
| 02/13/2025 | Date of filing of the Schedule 13G. |
Keywords
Collegium Pharmaceutical, Rubric Capital Management, David Rosen, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Pharmaceuticals, Investment Adviser, Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.